Zilebesiran Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Zilebesiran Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 3
Highest phase
8
Registered trials
9
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Zilebesiran can convert its siRNA profile and AGT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Zilebesiran (query alias: zilebesiran) |
|---|---|
| Modality / target | siRNA; AGT; AGT inhibitors, RNAi |
| Highest global status | Phase 3 |
| Originator | Alnylam Pharmaceuticals, Inc. |
| Active developers | Alnylam Pharmaceuticals, Inc., Roche Holding AG |
The MCP disease footprint includes Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07181109 | Phase 3 | Recruiting | 11000 | Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit) |
| NCT07553442 | Phase 2 | Recruiting | 93 | Part A: Percentage recovery from baseline in serum AGT |
| NCT06423352 | Phase 1/2 | Completed | 36 | Number of Participants With Adverse Events (AEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
Phase 1/2; n=36; evaluation: not stated. Reported fields: Treatment-emergent AEs, n (%) = 4 Participants ; Treatment-emergent AEs, n (%) = 6 Participants ; -
KARDIA-3 trial examines blood-pressure lowering effects of zilebesiran in hypertensive patients at high cardiovascular risk
Phase 2; n=270; evaluation: Negative. Reported fields: office SBP(placebo-adjusted mean change, 3-month) = -3.3 mmHg (95%CI, -8.2 to 1.6); office SBP(placebo-adjusted mean change, 3-month) = -5.0 mmHg (95%CI, -9.9 to -0.2); -
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Phase 2; n=672; evaluation: Positive. Reported fields: SBP(24-Hour; 3 month) = - 4.0 mmHg Met; - Met; SBP(24-Hour; 3 month) = - 12.1 mmHg Met
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Zilebesiran addresses Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—siRNA—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-04-19 | Chugai In-Licenses RNAi Therapeutic Zilebesiran for Hypertension with High Cardiovascular Risk | Phase 2 | Financial terms not disclosed |
| 2023-07-24 | Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RN | Phase 2 | US$310.0M upfront; US$2,800.0M milestones |
| 2020-04-13 | Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics | NDA/BLA | US$2,000.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods and compositions for treating an angiotensinogen- (AGT-) associated disorder”. The milestone feed surfaced a patent-application signal described as “Methods and compositions for treating an angiotensinogen- (AGT-) associated disorder”. The milestone feed surfaced a patent-application signal described as “Methods and compositions for treating angiotensinogen (AGT) related conditions”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
